Andrew Pollack - May 12 2015 (New York Times) A study of an obesity drug has ended after the manufacturer released early and ultimately misleading data, researchers said on Tuesday.
The company, Orexigen Therapeutics, disclosed in March that early results from a clinical trial of its drug Contrave had shown a 41 percent reduction in the risk of heart attacks, strokes and death from cardiovascular causes. Orexigen’s stock shot up, and the information no doubt helped lift sales of Contrave.
But the academic researchers who oversaw the study said on Tuesday that Orexigen had violated an agreement that the early results were not going to be shared widely, even within the company.
Read the full article on NYTimes.com